Evidence mapPaperPMID 41013206Full record

ArticleMolecular medicine (Cambridge, Mass.)2025

Anti-P antibodies that impair memory perturb hippocampal glutamatergic receptor trafficking, synapse structure and microglia.

Nicole Díaz-Valdivia, Mariana Labarca, Claudio Retamal, Sofia Espinoza, Jaime Venegas, Alejandra Catenaccio, Adely de la Peña, Micaela Ricca, Claudia Jara, Daniela Cortés-Díaz and 12 more

Abstract read
In one paragraph

Article in Molecular medicine (Cambridge, Mass.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Nicole Díaz-Valdivia *Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Mariana Labarca *Centro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Claudio RetamalCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Sofia EspinozaCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Jaime VenegasCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Alejandra CatenaccioCentro Científico y Tecnológico de Excelencia, Ciencia & Vida, Fundación Ciencia & Vida, 8580704, Huechuraba, Santiago, Chile.
Adely de la PeñaCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Micaela RiccaCentro Científico y Tecnológico de Excelencia, Ciencia & Vida, Fundación Ciencia & Vida, 8580704, Huechuraba, Santiago, Chile.
Claudia JaraCentro Científico y Tecnológico de Excelencia, Ciencia & Vida, Fundación Ciencia & Vida, 8580704, Huechuraba, Santiago, Chile.
Daniela Cortés-DíazFacultad de Medicina, Universidad San Sebastián, 7510157, Santiago, Chile.
Angela CamposCentro Científico y Tecnológico de Excelencia, Ciencia & Vida, Fundación Ciencia & Vida, 8580704, Huechuraba, Santiago, Chile.
Francisca Pérez-MolinaCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Francisca BarakeCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Bernardita MedelCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Cristian Herrera-CidCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Fanny GuzmanNúcleo de Biotecnología Curauma, Pontificia Universidad Católica de Valparaíso, Av. Universidad 330, 2373223, Curauma, Valparaíso, Chile.
Bredford KerrCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Manuel Varas-GodoyCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Marcela Bravo-ZehnderCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile.
Loreto MassardoFacultad de Medicina, Universidad San Sebastián, 7510157, Santiago, Chile.
Cheril Tapia-RojasFacultad de Ciencias, Universidad San Sebastián, 7510157, Santiago, Chile. cheril.tapia@uss.cl.
Alfonso GonzálezCentro de Biología Celular y Biomedicina (CEBICEM), Facultad de Ciencias, Universidad San Sebastián, Av. Del Valle Norte 725, 8580704, Huechuraba, Santiago, Chile. alfonso.gonzalez@uss.cl.

Funding

Agencia Nacional de Investigación y Desarrollo Programa Becas Doctorado Nacional, Grant/Award Number: #21230642 (N.D-V) and #21212192 (J.V)Centro Científico Tecnológico de Excelencia Ciencia & Vida Basal Project FB210008, (A.G, C.T-R, M.V-G.)Fondo Nacional de Desarrollo Científico y Tecnológico #1221796 (A.G), #1221178 (C.T-R), #1230905 (B.K), #1210056 (F.G), #1230983 (M.V-G.)Fondo Nacional de Desarrollo Científico y Tecnológico Postdoctoral #3210493 (S.E)Vicerrectoría de Investigación y Doctorados de la Universidad San Sebastián USS-FIN-24-CNGD-22
6 · The paper itself

Abstract

backgroundAnti-ribosomal P protein autoantibodies (anti-P) are associated with psychosis and cognitive dysfunction in patients with systemic lupus erythematosus (SLE), yet the underlying mechanisms remain undefined, hindering targeted therapies. Anti-P cross-react with a neuronal surface protein (NSPA), alter glutamatergic synaptic transmission and plasticity in hippocampal slices, and impair spatial memory in a short-term passive transfer mouse model. NSPA knockout mice display spatial memory deficit linked to reduced NMDAR activity and postsynaptic density (PSD) levels, along with an increased membrane-associated tyrosine phosphatase PTPMEG, suggesting disrupted glutamatergic receptor trafficking. Here, we investigated the acute effects of anti-P on receptor cell surface expression and trafficking in cultured hippocampal neurons and their long-term impact on hippocampal components and spatial memory in anti-P( +) immunized mice.

methodsNMDAR and AMPAR surface expression and NMDAR recycling were assessed in 21-24 DIV primary hippocampal neurons by immunofluorescence and FRAP using SEP-tagged receptors under the effects of rabbit anti-P IgG fractions. In vivo, female C57BL/6 mice were immunized with recombinant P0 ribosomal protein to induce anti-P, followed by lipopolysaccharide (LPS) intraperitoneal administration to breach the blood-brain-barrier (BBB). Spatial memory was evaluated with a water maze memory flexibility test. Hippocampal synaptosomal membranes and PSD-enriched fractions were analyzed by immunoblotting. Neuronal density, microglia and dendritic architecture were evaluated using Cresyl Violet, Iba1 and Golgi staining, respectively.

resultsAnti-P treatment of cultured neurons reduced GluN2A and GluA1 surface levels and impaired SEP-GluN2A and SEP-GluN2B recycling. Anti-P( +) mice showed spatial memory deficits persisting up to 24 days post-LPS, along with hippocampal alterations that include reduced levels of NMDAR, AMPAR, and PSD-95 in PSD fractions; increased membrane-associated PTPMEG; ~ 7% neuronal loss; higher number of microglia with reduced ramifications, and diminished dendritic width and spine density. Notably, increased PTPMEG levels were already detectable by day 10 post-LPS.

conclusionsAnti-P antibodies acutely impair glutamatergic receptor recycling and surface expression, while their long-term effects lead to sustained memory impairment associated with altered neuronal and microglial architecture, and PTPMEG increased levels preceding PSD protein loss. These findings provide mechanistic insight into anti-P-mediated cognitive dysfunction and may inform therapeutic strategies for neuropsychiatric SLE.

Indexed as

AutoantibodiesHippocampusMemory DisordersMicrogliaReceptors, GlutamateReceptors, N-Methyl-D-AspartateRibosomal ProteinsSynapsesAnimalsCells, CulturedFemaleMiceMice, Inbred C57BLNeuronsProtein TransportReceptors, AMPAAutoantibodiesReceptors, AMPAReceptors, GlutamateReceptors, N-Methyl-D-AspartateRibosomal ProteinsAnti-ribosomal P antibodiesCognitive dysfunctionNeuronal-surface-P-antigenNeuropsychiatric SLENMDAR and AMPAR traffickingNSPAPSD-95PTPMEGSynaptic plasticity

Identifiers

PMID41013206
PMCPMC12465742

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.